David M Mott

US Patent:

7375136, May 20, 2008

Filed:

Mar 8, 2002

Appl. No.:

10/469824

Inventors:

Stephen F. Traynelis - Decatur GA, US
Dennis C. Liotta - Atlanta GA, US
James P. Snyder - Atlanta GA, US
Yesim Altas - Decatur GA, US
David D. Mott - Tucker GA, US
Raymond J. Dingledine - Atlanta GA, US

Assignee:

Emory University - Atlanta GA

International Classification:

A61K 31/18
C07C 311/18

US Classification:

514605, 564 99

Abstract:

NMDA receptor blockers, including pH-sensitive NMDA receptor blockers, are provided as neuroprotective drugs that are useful in stroke, traumatic brain injury, epilepsy, and other neurologic events that involve acidification of brain or spinal cord tissue. Compositions and methods of this invention are used for treating neurodegeneration resulting from NMDA receptor activation. The compounds described herein have enhanced activity in brain tissue having lower-than normal pH due to pathological conditions such as hypoxia resulting from stroke, traumatic brain injury, global ischemia that may occur during cardiac surgery, hypoxia that may occur following cessation of breathing, pre-eclampsia, spinal cord trauma, epilepsy, chronic pain, vascular dementia and glioma tumors. Compounds described herein are also useful in preventing neurodegeneration in patients with Parkinson's Alzheimer's, Huntington's chorea, ALS, and other neurodegenerative conditions known to the art to be responsive to treatment using NMDA receptor blockers. Preferably the compounds provided herein are allosteric NMDA inhibitors.

US Patent:

20090023791, Jan 22, 2009

Filed:

May 8, 2008

Appl. No.:

12/151633

Inventors:

Stephen F. Traynelis - Decatur GA, US
Dennis C. Liotta - Atlanta GA, US
James P. Snyder - Atlanta GA, US
Yesim Altas - Decatur GA, US
David D. Mott - Tucker GA, US
Raymond J. Dingledine - Atlanta GA, US

Assignee:

Emory University - Atlanta GA

International Classification:

A61K 31/421
C07C 311/01
A61K 31/18
A61K 31/13
A61P 25/00
C07C 211/01
C07C 311/15
C07D 263/30

US Classification:

514376, 564 95, 514605, 548229, 564 84, 514604, 564374, 514654

Abstract:

NMDA receptor blockers, including pH-sensitive NMDA receptor blockers, are provided as neurprotective drugs that are useful in stroke, traumatic brain injury, epilepsy, and other neurologic events that involve acidification of brain or spinal cord tissue. Compositions and methods of this invention are used for treating neurodegeneration resulting from NMDA receptor activation. The compounds described herein have enhanced activity in brain tissue having lower than normal pH due to pathological conditions such as hypoxia resulting from stroke, traumatic brain injury, global ischemia that may occur during cardiac surgery, hypoxia that may occur following cessation of breathing, pre-eclampsia, spinal cord trauma, epilepsy, chrounic pain, vascular dementia and glioma rumors. Compounds described herein are also useful in preventing neurodegeneration in patients with Parkinson's Alzheimer's, Huntington's chorea, ALS, and other neurodegenerative conditions known to the art to be responsive to treatment using NMDA receptor blockers. Prefebably the compounds provided herein are allosteric NMDA inhibitors.